Aida Pharmaceuticals, Inc. is working on a new wide-spectrum antibiotic that was discovered by its recently acquired affiliate, the Jiangsu Institute of Microbiology Co., Ltd (JSIM). Wetimicin, which belongs to a new generation of amino-glycoside antibiotics, is in Phase I trials. Aida believes the product will have a wider market than its current antibiotic, Etimicin Sulphate. In its various forms, Etimicin Sulphate produced the majority of Aida’s $29 million of revenues in 2007. Etimicin Sulphate belongs to the same family of antibiotics as Wetimicin. More details...

Stock Symbol: (OTCBB: AIDA)